文献速递肝病消化道肿瘤与早癌消化内镜

肝硬化患者钆塞酸二钠增强MRI上肝细胞癌、早期肝细胞癌及高级别异型增生结节的新标志物:一种新诊断算法

New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm.
PubMed 文献 · Gut · 2018-02-03

该前瞻性研究纳入228例患者的420个大于1 cm结节,评估钆塞酸二钠增强MRI及弥散加权成像对肝细胞癌、早期肝细胞癌和高级别异型增生结节的诊断标准,基于肝胆期低信号、动脉期高信号和弥散受限建立新诊断算法,其敏感度高于美国肝病研究学会标准且特异度相当。

要点

  • 新算法对肝细胞癌/早期肝细胞癌的敏感度为96%,特异度为91.8%,敏感度高于美国肝病研究学会标准(P<0.001)。
  • 对≤2 cm结节,新算法敏感度为96.6%(P<0.001),特异度为92.7%(P=0.125)。
  • 新算法分类高级别异型增生结节的敏感度为94.7%,特异度为99.3%。

核心结论

  • 在肝硬化患者中,基于钆塞酸二钠增强MRI的新诊断算法对肝细胞癌的敏感度显著高于美国肝病研究学会影像标准且特异度相当,对≤2 cm病灶亦然。
  • 该诊断算法还可用于评估肝硬化肝脏中可能出现的其他病变,如早期肝细胞癌和高级别异型增生结节。

研究设计与样本

  • 前瞻性研究,纳入228例患者的420个大于1 cm结节。
  • 收集所有序列/期相MRI表现,肝细胞癌诊断依据美国肝病研究学会标准,所有不典型结节经组织学诊断。
  • 采用分类与回归树方法,基于三个独立显著相关变量(肝胆期低信号、动脉期高信号和弥散受限)建立新诊断算法。

主要发现

  • 新算法在全研究人群中的敏感度为96%(95%CI 93.5%至97.6%),特异度为91.8%(95%CI 88.6%至94.1%)。
  • 新算法对≤2 cm结节的敏感度为96.6%(95%CI 93.9%至98.5%),特异度为92.7%(95%CI 88.9%至95.4%)。
  • 与美国肝病研究学会标准相比,新算法敏感度更高(全人群P<0.001;≤2 cm结节P<0.001),特异度略低(全人群P=0.063;≤2 cm结节P=0.125)。
  • 新算法分类高级别异型增生结节的敏感度为94.7%(95%CI 92%至96.6%),特异度为99.3%(95%CI 97.7%至99.8%)。

关键数值与推荐

  • 新诊断算法依次应用肝胆期低信号、动脉期高信号和弥散受限三个MRI表现。
  • 肝细胞癌诊断参照美国肝病研究学会标准。
  • 所有不典型结节经组织学诊断。

临床怎么用

  • 作者建议在肝硬化患者中使用钆塞酸二钠增强MRI并采用该新诊断算法评估肝细胞癌、早期肝细胞癌和高级别异型增生结节。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Many improvements have been made in diagnosing hepatocellular carcinoma (HCC), but the radiological hallmarks of HCC have remained the same for many years. We prospectively evaluated the imaging criteria of HCC, early HCC and high-grade dysplastic nodules (HGDNs) in patients under surveillance for chronic liver disease, using gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) MRI and diffusion-weighted imaging. DESIGN: Our study population included 420 nodules >1 cm in 228 patients. The MRI findings of each nodule were collected in all sequences/phases. The diagnosis of HCC was made according to the American Association for the Study of Liver Diseases (AASLD) criteria; all atypical nodules were diagnosed using histology. RESULTS: A classification and regression tree was developed using three MRI findings which were independently significant correlated variables for early HCC/HCC, and the best sequence of their application in a new diagnostic algorithm (hepatobiliary hypointensity, arterial hyperintensity and diffusion restriction) was suggested. This algorithm demonstrated, both in the entire study population and for nodules ≤2 cm, higher sensitivity (96% [95% CI 93.5% to 97.6%] and 96.6% [95% CI 93.9% to 98.5%], P<0.001, respectively) and slightly lower specificity (91.8% [95% CI 88.6% to 94.1%], P=0.063, and 92.7% [95% CI 88.9% to 95.4%], P=0.125, respectively) than those of the AASLD criteria. Our new diagnostic algorithm also showed a very high sensitivity (94.7%; 95% CI 92% to 96.6%) and specificity (99.3%; 95% CI 97.7% to 99.8%) in classifying HGDN. CONCLUSION: Our new diagnostic algorithm demonstrated significantly higher sensitivity and comparable specificity than those of the AASLD imaging criteria for HCC in patients with cirrhosis evaluated using Gd-EOB-DTPA MRI, even for lesions ≤2 cm. Moreover, this diagnostic algorithm allowed evaluating other lesions which could arise in a cirrhotic liver, such as early HCC and HGDN.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Renzulli M, Biselli M, Brocchi S, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut. 2018. PMID: 29437912. doi:10.1136/gutjnl-2017-315384

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。